Niagen Bioscience, Inc. current report, 07 January 2020

SEC Filing Summary: ChromaDex Corporation (8-K)

Business Context and Reporting Period

This Form 8-K Current Report was filed by ChromaDex Corporation on January 10, 2020, regarding events occurring on January 7, 2020. The filing addresses Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive personnel changes and does not contain financial performance data.

Material Changes

  • Departure: Lisa Bratkovich ceased serving as Chief Marketing Officer effective January 10, 2020.
  • Succession: Megan Jordan, previously Chief Communications Officer since August 2019, assumed the additional role of Senior Vice President of Global Marketing.
  • Reporting Line: Ms. Jordan will continue to report directly to Robert Fried, Chief Executive Officer.

Compensatory Arrangements and Management Commentary

Ms. Bratkovich entered into a Separation Agreement with the following terms:

  • Continuation of base salary for 12 months.
  • Accelerated vesting of time-based equity that would have vested by the one-year anniversary of the termination date.
  • A three-year period post-termination to exercise vested stock options.
  • Payment of COBRA group health insurance premiums for up to 12 months.
  • Agreement includes mutual non-disparagement and a standard release of claims.

The full text of the Separation Agreement is to be filed as an exhibit to the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2020.

Investor Verification Checklist

  • Verify the exact terms of the Separation Agreement in the upcoming Form 10-Q for the quarter ended March 31, 2020.
  • Confirm the impact of the leadership transition on the Company's global marketing strategy.
  • Review subsequent filings for any additional executive departures or appointments.